Uncover the 11 best face washes for every skin type—hand-tested by our team and expert-approved to keep your skin clean, healthy, and glowing.

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint ...

FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data –– Positive biosimilarity ...

Q3 2025 Earnings Call Transcript November 13, 2025Protalix BioTherapeutics, Inc. misses on earnings expectations.

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform ...

Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with ...

Menstrual cramps are the only type of pain that we as human beings accept as a normal phenomenon. That makes them far too ...

General and Administrative (G&A) expenses: G&A expenses totaled $5.4 million for the third quarter ended September 30, 2025, compared to $1.4 million for the quarter ended September 30, 2024. G&A ...

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform ...

Arcutis Biotherapeutics announced strong third-quarter 2025 results, reporting revenue of $99.2 million and achieving profitability for the first time, which surpassed analyst expectations. Following ...

Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...

The CISCE has unveiled the 2026 ICSE Class 10 exam timetable, with examinations commencing on February 17 and concluding on ...